Follistatin-344: The Ovarian Protein That Turned Out to Be Muscle’s Strongest Brake Release
A full UK research guide to Follistatin-344: the reproductive-biology discovery it is named after, what the 344, 315, 303 and 288 forms actually are and why the difference decides what a preparation can do, how follistatin cages and di…
On this page
- A Protein Named After the Smaller Half of Its Job
- FST344, FST315 and FST288: The Three Numbers Everyone Mixes Up
- How Follistatin Switches a Signal Off
- What the Muscle Studies Measured, Weakest Species First
- Where Follistatin Reached People, and What Actually Happened
- The Honest Problem: This Is a Glycoprotein, Not a Peptide
- Follistatin Outside Muscle
- Regulatory and Sporting Position in the UK
- Technical Breakdown for the Detail-Minded
- What a Batch Certificate Can and Cannot Tell You
- Related Molecules in the Same Pathway
- Common Questions About Follistatin-344
- A Big Molecule With a Small Evidence Base in People
- References
In 2007 Se-Jin Lee published a mouse that should not have been possible. Animals already lacking the myostatin gene — the famous double-muscled mice, twice as heavy in the muscle as normal — were crossed with a line carrying extra follistatin in skeletal muscle. The offspring had about four times the muscle mass of wild-type animals (PMID: 17726519). Deleting myostatin was supposed to be the ceiling; follistatin went straight through it, so myostatin is only one of several molecules holding muscle back. Stranger still is where follistatin came from: pig ovarian fluid, named for a reproductive job.
That molecule is what Crown Peptides supplies as the Follistatin-344 Research Compound, listed under Musculoskeletal research peptides and sitting just as naturally beside the Endocrine & Hormonal research peptides. It is laboratory material, sold for research use only like everything we stock, and this guide reports only what has been published. Read it with one fact in mind: follistatin is not a short synthetic peptide. It is a glycoprotein whose precursor runs to 344 residues, and the distance between that and a vial of powder is the most interesting question here.
- What it is
- A secreted, cysteine-rich glycoprotein whose main targets are the activins, myostatin (GDF-8) and GDF-11, with weaker binding to BMP-6 and BMP-7 and none to BMP-2 or BMP-4
- Why "344"
- The length of one of two alternatively spliced precursors; once the signal sequence is removed it becomes the 315-residue circulating protein
- The other numbers
- FST315 circulates in blood, FST288 binds cell surfaces, FST303 sits between them
- Discovered
- 1987, in pig follicular fluid, as an inhibitor of FSH release
- Strongest evidence
- Mouse genetics and gene delivery; one primate study; open-label human gene therapy in twelve people; randomised placebo-controlled phase 2 trials of a follistatin-based protein
- Where it stops
- No licensed follistatin medicine anywhere; the best-controlled trials grew muscle without improving function
- Sporting status
- Prohibited in human sport and in horseracing, with validated detection methods
- Supplied as
- Freeze-dried powder in a sealed vial
A Protein Named After the Smaller Half of Its Job
Ovarian fluid plainly held more follicle-stimulating-hormone-suppressing activity than inhibin could account for, so in the mid-1980s people went looking for the rest. A Salk Institute group pulled porcine follicular fluid apart by heparin-Sepharose chromatography, gel filtration and repeated HPLC. Out came a single-chain, cysteine-rich protein of about 35,000 daltons with no resemblance to the inhibins, which suppressed basal FSH in rat anterior pituitary culture at a half-maximal effective dose of 2.5 to 6.0 ng/ml and left luteinising hormone alone (PMID: 3120188). They named it follistatin to mark that structural difference, and the heparin column they purified it on turned out to be a clue.
Follistatin is a real but modest FSH regulator. Castrated rams given human recombinant follistatin-288 intravenously, a 50 µg bolus then a twelve-hour 800 µg infusion, dropped plasma FSH by 20.6% — about 2.6-fold less than the same regimen of recombinant inhibin A, luteinising hormone unmoved (PMID: 8562691). The subject changed in 1990, when a Japanese group purified an activin-binding protein from rat ovary and found it was follistatin (PMID: 2106159). The FSH effect was downstream of mopping activin up, and since the transforming growth factor-beta family includes myostatin, the road to the muscle literature opened the moment that sequence was read. Our guide to Peptide Hormones Explained covers this class of signal.
FST344, FST315 and FST288: The Three Numbers Everyone Mixes Up
One gene, two messages, one extra exon
Follistatin was characterised in the pig, by microsequencing and cDNA cloning, in the year of its isolation. Two clone populations turned up, differing in their three-prime untranslated sequences: one encoded a precursor of 344 amino acids, the other an identical but carboxyl-terminally truncated precursor of 317 (PMID: 3153465). The human sequence followed from a testis cDNA library — three of eight clones predicted 344 residues, five predicted 317, by alternative splicing of one messenger RNA (PMID: 3380788). The porcine gene shows the mechanism in full: six exons across about six kilobases, the first encoding the signal sequence, the next four the mature domains, the last the extra 27 residues separating the two precursors (PMID: 3365249). The human gene is laid out the same way (PMID: 3380788). Splice that final exon in, you get 344; splice it out, 317.
Precursors and mature proteins are not the same thing
Here is where most writing on this compound goes wrong. 344 and 317 are precursor lengths, signal sequence still attached; 315 and 288 are what remains once that sequence is cut off on secretion. In the annotated human reference sequence the signal peptide is residues 1 to 29, experimentally determined, so the 344-residue precursor yields a 315-residue mature protein — the length the first characterisation reported (PMID: 3153465). Strip those 29 from the 317-residue precursor and you have 288. FST344 and FST315 are therefore one molecule at two stages of life, as are FST317 and FST288, which is why a paper about FS344 and one about FS315 may be describing the same thing. One wrinkle: the tail is usually given as 27 residues, consistent with 315 minus 288, though one widely cited paper calls it 26 (PMID: 15472207).
Why the tail is the whole argument
A third form, FST303, sits between them, thought to come from proteolytic trimming of FST315's tail. All three bind cell-surface proteoglycans, in the strict order FST288 > FST303 > FST315, and an assay specific for full-length FST315 confirmed it: FST315 is the major circulating form, undetectable in follicular fluid aspirated from normal women or women with polycystic ovary syndrome (PMID: 15472207). So the long form, which is what a vial labelled 344 refers to, is the blood-borne one and the short form is tissue-anchored. The useful conclusion is subtler, and easy to lose in the chemistry: the long form is not a weaker molecule but one whose cell-surface behaviour is switched on by catching a ligand — free in blood it stays mobile, loaded with activin it gains the surface affinity that sends the whole complex for disposal.
The mechanism is electrostatic. The heparin and heparan sulphate binding site is a lysine-rich stretch from Lys75 to Arg86: every fragment of the digested 288-residue protein retained on a sulphated column began at residue 68, and a synthetic 72-to-86 peptide competed with the whole protein for heparin (PMID: 1301390). The long form's extra tail carries a strongly acidic run of glutamates and aspartates at residues 292 to 304, its last eleven uncharged (PMID: 3153465) — an acidic stretch folding back over a basic patch. The structures then complicate that picture: measured side by side both isoforms bind heparin with similar affinity at low ionic strength, FST315 falling away more steeply as salt rises, and once FST315 is bound to activin its acidic residues cannot reach the heparin site at all — which is where the switch comes from, and may be how such complexes are cleared (PMID: 17409095).
What a label reading "Follistatin-344" is naming
The long splice variant, whose mature secreted product is the 315-residue circulating protein — and also what the gene therapy field chose. Reviewing their own programme, the Nationwide Children's Hospital group said FS344 was picked because its product FS315 is serum-based and, on their account, binds activin around tenfold more weakly than FS288, limiting interference with the pituitary activin-inhibin axis (PMID: 27858738). That tenfold figure needs a flag: a direct comparison of recombinant FST288, FST303 and FST315 found comparable activin affinities, with cell-surface binding the thing that differed — in one assay FST288 suppressed activin-dependent proliferation while FST315 enhanced it (PMID: 16627583). Both agree the long form is the more systemic choice; they disagree why. These isoforms are separated above all by where they can go.
How Follistatin Switches a Signal Off
Most antagonists sit in a receptor. Follistatin is more thorough: the crystal structure of activin A bound to follistatin showed two follistatin molecules encircling the ligand, burying about a third of its residues and both receptor-binding surfaces. The surprise was follistatin's N-terminal domain, which adopts an unexpected fold mimicking a universal type I receptor motif and parks itself in the type I site — something earlier models assumed it could not block (PMID: 16198295). Less a competitive equilibrium than a cage.
A surface that appears from nowhere
The myostatin complex, solved four years later, added the detail that makes the mechanism click. Docking creates a continuous electropositive surface present on neither protein alone, sharply raising the complex's affinity for heparin, strengthening its grip on the cell surface and accelerating myostatin's degradation — with either the 288 or the 315 form (PMID: 19644449). That is a disposal system, not a blockade: the binding event generates the address label.
Different domains, different ligands, and how tight the grip is
The three domains are not redundant. Point mutants and domain swaps put activin binding mainly on the second follistatin domain and myostatin binding more on the first; deleting the second, or duplicating the first in its place, gave molecules that antagonised myostatin with far less activin antagonism, though they still bound GDF-11 (PMID: 18535106). The myostatin grip is tight and needs the whole protein: kinetics put the direct interaction at 5.84 × 10⁻¹⁰ M, single modules could not associate with myostatin at all, and follistatin blocked myostatin's collapse of Pax-3 and MyoD expression in chick limb buds (PMID: 15136138). Competitive binding puts myostatin ahead of bone morphogenetic proteins 6 and 7, with BMPs 2 and 4 inactive (PMID: 16627583). So "binds the TGF-beta family" is both too loose and too narrow: the activins, myostatin and GDF-11 are the main targets, BMP-6 and BMP-7 bind more weakly, BMP-2 and BMP-4 not at all.
What the Muscle Studies Measured, Weakest Species First
Taking the gene away, then putting extra in
Mice engineered without follistatin do not survive. They are growth-retarded, with reduced diaphragm and intercostal muscle mass, taut shiny skin, skeletal defects in the palate and ribs and abnormal whisker and tooth development; they fail to breathe and die within hours of birth — a wider spread of defects than in activin-deficient mice, which the authors read as evidence that follistatin modulates several family members (PMID: 7885475). Losing one copy is more informative than losing both: heterozygous mice have significantly smaller muscles, a shift towards oxidative fibre types, impaired remodelling after cardiotoxin injury and reduced tetanic force, though specific force holds. That is at least partially retained in a myostatin-null background, meaning follistatin restrains something besides myostatin — and the genetic evidence pointed at activin A (PMID: 20810712).
The gain-of-function experiment came earlier. Purified myostatin's C-terminal dimer binds the activin type IIB receptor — whose soluble decoy version is sold as ACE-031 Research Peptide — and type IIA less well; follistatin inhibited that binding, and transgenic mice expressing follistatin from a muscle-specific promoter gained muscle mass comparably to myostatin knockouts (PMID: 11459935). The quadrupling result above is the follow-up, with an oddity attached: the largest effects appeared in offspring of mothers homozygous for the myostatin mutation, suggesting myostatin or something downstream crosses from maternal to foetal circulation (PMID: 17726519).
One administration, two years of effect
Transgenic animals say what a pathway can do, not whether you could act on an adult. One gene administration of myostatin-inhibitor proteins answered that: muscle mass and strength rose in normal and dystrophic mice for over two years, including in aged animals (PMID: 18334646). In C57BL/6J mice aged 24 to 27 months, follistatin overexpression from a self-complementary adeno-associated virus raised muscle weight and torque and improved innervation and transmission at the neuromuscular junction — but left the age-related loss of motor units untouched (PMID: 33964607). Bigger, better-connected fibres; the same number of surviving nerve supplies. Sobering for anyone reading follistatin as an answer to sarcopenia.
The macaque study, and the notice attached to it
FS344, chosen for muscle selectivity and minimal effect on non-muscle cells, was expressed from an adeno-associated virus serotype 1 vector and delivered intramuscularly into the quadriceps of cynomolgus macaques. Muscle size and strength rose markedly and held, while long-term transgene expression left the major organs unaltered in morphology and function (PMID: 20368179). One thing must be said about it: in August 2026 the journal issued a formal erratum. The notice does not say publicly what was corrected, so this guide will not speculate — but it will tell you the notice exists, because this paper is the pre-clinical foundation the human trials were built on. It has not been retracted and carries no expression of concern.

Follistatin-344 Research Compound
Out of stock · every batch HPLC and MS tested
View Follistatin-344 Research Compound ›Where Follistatin Reached People, and What Actually Happened
Six men with Becker muscular dystrophy
AAV1.CMV.FS344 went into both quadriceps of six people with Becker muscular dystrophy in a phase 1/2a trial. Three received 3 × 10¹¹ vector genomes per kilogram per leg: two improved their six-minute walk distance by 58 and 125 metres, the third not at all. Three received double that: two by 108 and 29 metres, one nothing. No adverse effects were encountered, and biopsies showed less endomysial fibrosis, less central nucleation and a more normal fibre size distribution (PMID: 25322757). Four of six moving the right way is interesting in a progressive disease; six patients with no control group is also, unavoidably, proof of principle.
Inclusion body myositis, and a published argument about it
The same vector at 6 × 10¹¹ vg/kg went into the quadriceps of six people with sporadic inclusion body myositis, alongside a prescribed exercise programme. The reported outcome was an annualised change in six-minute walk distance of +56.0 metres per year in treated subjects against −25.8 in eight untreated patients matched for age, sex and baseline (p = 0.01); four of six improved by 58 to 153 metres, two by 5 to 23 (PMID: 28279643).
Six months later the same journal published a letter from a neurologist at Brigham and Women's Hospital calling the functional claims unfounded (PMID: 28927986). His objections are specific. Treated patients received four potentially active interventions at once — the gene therapy, about sixty days of high-dose prednisone, a monitored exercise programme and the expectation effects of an open-label study — while the comparator group, drawn from an ordinary clinic, was matched for none of them. He argued too that the published primary outcome differs from the registry's, that the annualised walk distance is a post-hoc construction depending on the time point chosen, and that the p value turns on a comparator size settled after the fact.
The trial's senior author answered in the same issue, and the reply matters as much as the letter (PMID: 28939086). Safety, he wrote, is the registered primary outcome in any first-in-human gene therapy study with function secondary, and the outcomes and statistical plan were fixed before dosing and filed with the regulator and the oversight boards — so nothing about them was post hoc. He defended the matched historical comparator under ICH and European Medicines Agency guidance, noted the control measurements came from the same physical therapists, and said the prednisone was a safety board request to counter pre-existing immunity to the vector. What he conceded is as useful: exercise did influence function, cohorts this small cannot carry statistics, and the team never claimed to have cured the disease. No controlled replication has been published.
The experiment that was properly controlled, and the gap it exposed
A locally acting follistatin-based fusion protein, ACE-083, went through placebo-controlled trials — the closest anyone has come to a clean human test of the idea. First in humans: 58 healthy postmenopausal women, 42 on ACE-083 at 50 to 200 mg and 16 on placebo, into one rectus femoris or tibialis anterior. Muscle volume rose by a maximum mean of 14.5% and 8.9%, nothing serious appeared on safety, and mean strength did not shift (PMID: 29486514). In randomised phase 2 work in facioscapulohumeral muscular dystrophy, 55 of 58 participants evaluable, muscle volume rose 16.4% against placebo in the biceps brachii group and 9.5% in the tibialis anterior group, contractile volume up in both — and no consistent gain in functional or patient-reported measures over twelve months (PMID: 35428982). A 63-patient study in Charcot-Marie-Tooth disease type 1 or CMTX randomised 45 and treated 44: volume rose 13.5% against placebo and ankle dorsiflexion strength differed significantly, every other functional outcome did not (PMID: 35545446).
Three trials, one consistent finding: the muscle gets measurably bigger and what the patient can do stays roughly where it was. That gap has no agreed explanation and it is not unique to follistatin — the same disconnect has dogged the whole myostatin-pathway field, the story told in ACE-031 (Ramatercept): The Myostatin Trap Behind Modern Muscle Research. Serious work should be designed around that question, not around hypertrophy.
The Honest Problem: This Is a Glycoprotein, Not a Peptide
315 residues is a protein by any reckoning
Everything above concerns follistatin as a cell makes it: inside an animal, or in a bioreactor under pharmaceutical control. None of it is a vial of powder. BPC-157 is fifteen amino acids, ipamorelin five; mature follistatin is 315 residues folded around 36 cysteines, three of its four domains detectably similar to epidermal growth factor and to pancreatic secretory trypsin inhibitor (PMID: 3153465, PMID: 3380788). That many cysteines means a dense disulphide network, and the whole-protein requirement for myostatin binding (PMID: 15136138) says the network is load-bearing. A molecule like this is expressed in cells and folded by them, not assembled on a resin. What Are Peptides? and What Is a Peptide Bond? set out where the line is drawn, and Peptide Half-Life Explained why size changes clearance.
The sugars are not decoration
Recombinant human follistatin expressed in Chinese hamster ovary cells has two potential N-glycosylation sites, Asn95 and Asn259, both only partially occupied, so one preparation holds glycosylated and non-glycosylated molecules side by side, carrying fucosylated complex-type sugars (PMID: 15454184). That is not a uniform substance but a population, and its composition changes the pharmacology. A follistatin-315 Fc fusion — three putative sites once the antibody tail is added — proved heterogeneously glycosylated in CHO cells, and its sialic acid content drove how fast it cleared in mice and monkeys, enough that its developers wrote a sialic acid specification into manufacturing (PMID: 26354950).
Which leaves a genuine open question
So, plainly: how a research-grade follistatin preparation compares with natural, correctly glycosylated human follistatin is not known, and it is not knowable from the vial. Folding, disulphide pairing, glycosylation occupancy and sialic acid content belong to the expression system and the purification, and all bear on activity; chromatographic purity and a mass figure cannot settle them. That is not a reason to avoid it — it is the reason the first experiments in a serious follistatin programme should be characterisation experiments. Anyone calling a preparation equivalent to the protein in the published papers is claiming something nobody knows, the same discipline we applied to Dihexa.
Follistatin Outside Muscle
A liver hormone released by exercise
Healthy volunteers cycled for three hours with arterial-venous sampling across the working limb. Plasma follistatin rose, peaking around sevenfold three hours into recovery — and none of it came from the exercising leg. Mice swimming for an hour showed the same rise alongside more follistatin messenger RNA and protein in the liver (PMID: 21068158). Follistatin in blood is largely a liver product. That paper carries a 2015 erratum.
The metabolic signal that points the other way
Here the simple story breaks. In mice whose livers had been made insulin-resistant, excess liver follistatin turned up among the dysregulated hepatokines; knocking it down restored glucose tolerance, adipose insulin signalling and insulin's suppression of hepatic glucose output, while expressing follistatin in a healthy liver did the opposite. Knockdown also improved glucose tolerance in obese mice, and in diabetic patients having gastric bypass serum follistatin fell alongside glycated haemoglobin (PMID: 29867232). That paper carries a 2018 publisher correction, and it is a minor one: two mislabelled y-axes in one figure, nothing touching the findings.
Prospective human data agree. Across 4,060 people followed for nineteen years in Sweden, each standard deviation increase in plasma follistatin carried an adjusted hazard ratio of 1.24 for incident type 2 diabetes; in 883 Finns followed four years it was 1.31. High follistatin also tracked with adipose insulin resistance and fatty liver in a separate group of 210, and in human adipocytes it raised free fatty acid release dose-dependently (PMID: 34759311). More circulating follistatin goes with worse glucose handling, not better. Both can be true: a locally acting molecule that enlarges a muscle, and a systemic hormone that marks metabolic trouble. For that side of the range see Metabolic research peptides and Best Peptides for Weight Loss Research.
Regulatory and Sporting Position in the UK
No follistatin medicine has been licensed anywhere, in any form, for any indication; the human work above is early-phase gene therapy and phase 1 and 2 trials of a derived protein. In the UK it is supplied as laboratory material, a classification about declared purpose rather than a judgement on quality — Are Peptides Legal in the UK? and What Does "Research Use Only" Actually Mean? explain where the lines fall.
The sporting position is unusually concrete for a compound at this stage. Recombinant human follistatin is prohibited in human sport by the World Anti-Doping Agency and in horseracing under the International Federation of Horseracing Authorities agreement, and the detection methods are validated: an ELISA to screen equine plasma, then immunocapture with nano-liquid chromatography and high-resolution tandem mass spectrometry to confirm, detecting around 2.5 to 5 ng/ml (PMID: 37401514). Informal personal-use reports circulate online. They are not research data, and Crown Peptides does not condone personal or human use of anything we supply.
Technical Breakdown for the Detail-Minded
Numbering, glycoforms and handling
For the record, and checked residue by residue against the annotated human sequence: mature follistatin-315 carries 36 cysteines across four contiguous domains, the three repeated ones running roughly 66 to 135, 139 to 210 and 216 to 287, with the acidic stretch at 292 to 304 and the heparin-binding region at 75 to 86 (PMID: 3153465, PMID: 1301390, PMID: 3380788, PMID: 3365249). Expect any preparation to be a mixture of glycoforms, which is why mass spectrometry on a protein this size reads as a distribution rather than a sharp figure. Follistatin-344 Research Compound ships freeze-dried under seal, and two habits matter more here than for a fifteen-residue peptide: let the vial reach room temperature before the seal is broken, so nothing condenses onto cold powder, then handle the solution gently, because vortexing and repeated freeze-thaw cost a folded protein its structure and not merely its mass. Bacteriostatic Water is the usual diluent; Peptide Reconstitution covers technique, How Long Do Peptides Last? material already in solution, and Storage information the cold-and-dark basics.
What a Batch Certificate Can and Cannot Tell You
A certificate answers narrower questions than most people assume. Chromatography says how much of the powder is the target; mass spectrometry says the target is the molecule named, weighed against a range for a glycosylated protein rather than to the single dalton. Neither says how the chain folded or which glycans it carries — this compound's particular limitation, and why the section above matters. Both go on the Lab Reports page against the code stamped on your vial, so paperwork matches material. Beyond that, Peptide Testing UK covers what the instruments resolve, How to Read a Peptide Certificate of Analysis walks through a real document, How to Tell If Peptides Are Real the warning signs, and How to Choose a UK Peptide Supplier if you are comparing suppliers. Weekday orders placed by two in the afternoon are dispatched that day, orders over £100 ship free within the UK, and a question sent through the contact page gets an answer within one working day, sooner on WhatsApp.
Related Molecules in the Same Pathway
The decoy receptor on the other side
The nearest neighbour comes at the same brake from the opposite end. Follistatin wraps around the ligand; ACE-031 Research Peptide is a soluble copy of the receptor, catching myostatin before it lands on a cell. Its own trials, its halted programme and the thinking behind decoy receptors are laid out in ACE-031 (Ramatercept), which is why this page does not repeat them. The distinction worth keeping is architectural: a natural binding protein arrives with selectivity it evolved and a disposal route built into binding; a trap arrives with a long circulating life and an engineered ligand range.
Growth-factor signalling and the growth hormone family
Follistatin releases a brake; the compounds below push the accelerator. IGF-1 LR3 Research Peptide is a modified insulin-like growth factor built to escape its binding proteins (IGF-1 LR3 Peptide UK Guide), and MGF Research Peptide is based on a splice variant of IGF-1 appearing after muscle damage, with the longer-lasting PEG-MGF Research Peptide alongside it; see MGF Peptide UK and PEG-MGF UK. Upstream of the pituitary, Sermorelin Research Peptide and Ipamorelin Research Peptide work differently again, as Growth Hormone Peptides Explained and Peptide Stacking in Research set out.
Where the repair literature sits beside it
Follistatin enlarges a muscle and does nothing for the tendon that has to carry it, which is why the repair compounds are studied beside it rather than against it. BPC-157 Research Peptide and TB-500 (Thymosin Beta-4) Research Peptide have the deepest literature there, sold together as the BPC-157 + TB-500 Blend (Wolverine Stack) and set against each other in BPC-157 vs TB-500, while Cartalax Research Peptide reaches connective tissue from the bioregulator direction. Three guides map it: Best Peptides Being Researched for Muscle Growth, Best Peptides for Recovery Research and Best Peptides for Joint and Tendon Research. And because follistatin is so often filed with anabolic agents, Peptides vs Steroids explains why that misleads, with Are Peptides Safe? on judging safety in a young literature.
Common Questions About Follistatin-344
What is follistatin 344?
The longer of two alternatively spliced forms of the human follistatin precursor, 344 amino acids as translated. Once the 29-residue signal sequence comes off on secretion it becomes the 315-residue mature protein, the main form circulating in blood. Follistatin binds and neutralises the activins, myostatin and GDF-11, which is why muscle biology took an interest.
What is the difference between FST344, FST315 and FST288?
FST344 and FST315 are the same molecule before and after the signal sequence is cut off. FST288 comes from the shorter splice variant and lacks the final 27-residue tail. That missing tail is the whole difference in behaviour: FST288 binds heparan sulphate on cell surfaces strongly and stays in tissue, while FST315 circulates (PMID: 15472207). The structures add a twist — once FST315 binds activin its tail can no longer cover the heparin site, and it starts behaving like the short form (PMID: 17409095).
How would a research-grade preparation compare with natural follistatin?
Nobody knows, and that is the honest answer. Natural follistatin is folded and glycosylated by the cell that makes it, and the sugars vary from molecule to molecule even in carefully made recombinant material (PMID: 15454184), directly controlling how fast it clears (PMID: 26354950). Characterise a preparation before drawing conclusions from it.
Are peptides legal in the UK?
Yes. The molecules themselves are not controlled; what the law attends to is the purpose declared for them. A protein supplied, labelled and bought as a laboratory reagent sits in a different category from a licensed medicine or a consumer supplement, and follistatin has never been either. Its prohibition in sport is separate, with separate rules. Are Peptides Legal in the UK? works through the categories.
A Big Molecule With a Small Evidence Base in People
Few molecules in muscle biology have animal data this dramatic: quadrupled muscle mass in mice, two years of effect from one vector administration, durable gains in macaque quadriceps, better neuromuscular junctions in old mice. The human record beside it is thin and contested, the controlled trials grew muscle without moving function, and the primate paper carries an erratum. All of that is true at once, and a page giving you only the first sentence would do you no favours.
What makes it worth working on is that the open questions are tractable. Why does volume not become function? Does the long form behave differently from the short form in real tissue, as the structures predict? And what is actually in a given preparation? Those are assay questions, not mysteries. Any serious attempt starts with material whose identity and purity you can inspect on paper first: the Follistatin-344 Research Compound ships freeze-dried and sealed, with its certificate published under the batch code on the vial, with the rest of the research range alongside.
References
- Ueno N, Ling N, Ying SY, et al. Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone. Proc Natl Acad Sci U S A. 1987;84(23):8282-6. PMID: 3120188
- Esch FS, Shimasaki S, Mercado M, et al. Structural characterization of follistatin: a novel follicle-stimulating hormone release-inhibiting polypeptide from the gonad. Mol Endocrinol. 1987;1(11):849-55. PMID: 3153465
- Shimasaki S, Koga M, Esch F, et al. Primary structure of the human follistatin precursor and its genomic organization. Proc Natl Acad Sci U S A. 1988;85(12):4218-22. PMID: 3380788
- Shimasaki S, Koga M, Esch F, et al. Porcine follistatin gene structure supports two forms of mature follistatin produced by alternative splicing. Biochem Biophys Res Commun. 1988;152(2):717-23. PMID: 3365249
- Nakamura T, Takio K, Eto Y, et al. Activin-binding protein from rat ovary is follistatin. Science. 1990;247(4944):836-8. PMID: 2106159
- Matzuk MM, Lu N, Vogel H, et al. Multiple defects and perinatal death in mice deficient in follistatin. Nature. 1995;374(6520):360-3. PMID: 7885475
- Inouye S, Ling N, Shimasaki S. Localization of the heparin binding site of follistatin. Mol Cell Endocrinol. 1992;90(1):1-6. PMID: 1301390
- Schneyer AL, Wang Q, Sidis Y, et al. Differential distribution of follistatin isoforms: application of a new FS315-specific immunoassay. J Clin Endocrinol Metab. 2004;89(10):5067-75. PMID: 15472207
- Sidis Y, Mukherjee A, Keutmann H, et al. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology. 2006;147(7):3586-97. PMID: 16627583
- Lerch TF, Shimasaki S, Woodruff TK, et al. Structural and biophysical coupling of heparin and activin binding to follistatin isoform functions. J Biol Chem. 2007;282(21):15930-9. PMID: 17409095
- Thompson TB, Lerch TF, Cook RW, et al. The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Dev Cell. 2005;9(4):535-43. PMID: 16198295
- Cash JN, Rejon CA, McPherron AC, et al. The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding. EMBO J. 2009;28(17):2662-76. PMID: 19644449
- Schneyer AL, Sidis Y, Gulati A, et al. Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin. Endocrinology. 2008;149(9):4589-95. PMID: 18535106
- Amthor H, Nicholas G, McKinnell I, et al. Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis. Dev Biol. 2004;270(1):19-30. PMID: 15136138
- Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci U S A. 2001;98(16):9306-11. PMID: 11459935
- Lee SJ. Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS One. 2007;2(8):e789. PMID: 17726519
- Lee SJ, Lee YS, Zimmers TA, et al. Regulation of muscle mass by follistatin and activins. Mol Endocrinol. 2010;24(10):1998-2008. PMID: 20810712
- Haidet AM, Rizo L, Handy C, et al. Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc Natl Acad Sci U S A. 2008;105(11):4318-22. PMID: 18334646
- Kota J, Handy CR, Haidet AM, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med. 2009;1(6):6ra15 [Erratum: Sci Transl Med. 2026;18(861):eaek4223] PMID: 20368179
- Iyer CC, Chugh D, Bobbili PJ, et al. Follistatin-induced muscle hypertrophy in aged mice improves neuromuscular junction innervation and function. Neurobiol Aging. 2021;104:32-41. PMID: 33964607
- Mendell JR, Sahenk Z, Malik V, et al. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther. 2015;23(1):192-201. PMID: 25322757
- Al-Zaidy SA, Sahenk Z, Rodino-Klapac LR, et al. Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy. J Neuromuscul Dis. 2015;2(3):185-192. PMID: 27858738
- Mendell JR, Sahenk Z, Al-Zaidy S, et al. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Mol Ther. 2017;25(4):870-879. PMID: 28279643
- Greenberg SA. Unfounded Claims of Improved Functional Outcomes Attributed to Follistatin Gene Therapy in Inclusion Body Myositis. Mol Ther. 2017;25(10):2235-2237. PMID: 28927986
- Mendell JR. Reply to Letter to the Editor. Mol Ther. 2017;25(10):2238-2240. PMID: 28939086
- Glasser CE, Gartner MR, Wilson D, et al. Locally acting ACE-083 increases muscle volume in healthy volunteers. Muscle Nerve. 2018;57(6):921-926. PMID: 29486514
- Statland JM, Campbell C, Desai U, et al. Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy. Muscle Nerve. 2022;66(1):50-62. PMID: 35428982
- Thomas FP, Brannagan TH, Butterfield RJ, et al. Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease. Neurology. 2022;98(23):e2356-e2367. PMID: 35545446
- Tilbrook AJ, Clarke IJ, de Kretser DM. Human recombinant follistatin-288 suppresses plasma concentrations of follicle-stimulating hormone but is not a significant regulator of luteinizing hormone in castrated rams. Biol Reprod. 1995;53(6):1353-8. PMID: 8562691
- Hansen J, Brandt C, Nielsen AR, et al. Exercise induces a marked increase in plasma follistatin: evidence that follistatin is a contraction-induced hepatokine. Endocrinology. 2011;152(1):164-71 [Erratum: Endocrinology. 2015;156(3):1200] PMID: 21068158
- Tao R, Wang C, Stöhr O, et al. Inactivating hepatic follistatin alleviates hyperglycemia. Nat Med. 2018;24(7):1058-1069 [Publisher Correction: Nat Med. 2018;24(10):1628] PMID: 29867232
- Wu C, Borné Y, Gao R, et al. Elevated circulating follistatin associates with an increased risk of type 2 diabetes. Nat Commun. 2021;12(1):6486. PMID: 34759311
- Hyuga M, Itoh S, Kawasaki N, et al. Analysis of site-specific glycosylation in recombinant human follistatin expressed in Chinese hamster ovary cells. Biologicals. 2004;32(2):70-7. PMID: 15454184
- Datta-Mannan A, Huang L, Pereira J, et al. Insights into the Impact of Heterogeneous Glycosylation on the Pharmacokinetic Behavior of Follistatin-Fc-Based Biotherapeutics. Drug Metab Dispos. 2015;43(12):1882-90. PMID: 26354950
- Wong KS, Cheung HW, Choi YC, et al. Screening and confirmation of recombinant human follistatin in equine plasma for doping control purposes. Drug Test Anal. 2024;16(3):259-267. PMID: 37401514